相似文献
1
Viral shedding after p53 adenoviral gene therapy in 10 cases of esophageal cancer.
Cancer Sci. 2010 Jan;101(1):289-91. doi: 10.1111/j.1349-7006.2009.01381.x.
2
Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
Cancer Gene Ther. 2000 Jul;7(7):1069-76. doi: 10.1038/sj.cgt.7700214.
3
Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Cancer Sci. 2006 Jun;97(6):554-61. doi: 10.1111/j.1349-7006.2006.00206.x.
4
Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors.
Cancer Gene Ther. 2001 May;8(5):342-51. doi: 10.1038/sj.cgt.7700313.
5
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005.
6
Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens.
Hum Gene Ther. 2003 Jan 1;14(1):25-36. doi: 10.1089/10430340360464688.
7
A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens.
Ann Surg. 2003 Dec;238(6):815-24; discussion 825-6. doi: 10.1097/01.sla.0000098622.47909.c0.
8
Preclinical study of adenoviral p53 gene therapy for esophageal cancer.
Surg Today. 2001;31(7):597-604. doi: 10.1007/s005950170093.
9
In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection.
Surgery. 1994 Aug;116(2):197-203; discussion 203-4.
10
Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland.
J Gene Med. 2010 Jan;12(1):3-10. doi: 10.1002/jgm.1416.
引用本文的文献
1
Designing cytochrome P450 enzymes for use in cancer gene therapy.
Front Bioeng Biotechnol. 2024 May 24;12:1405466. doi: 10.3389/fbioe.2024.1405466. eCollection 2024.
2
p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.
Ann Gastroenterol Surg. 2018 Jun 13;2(4):266-273. doi: 10.1002/ags3.12179. eCollection 2018 Jul.
3
Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
Gene Ther. 2016 Jan;23(1):50-6. doi: 10.1038/gt.2015.84. Epub 2015 Aug 4.
4
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.
Clin Cancer Res. 2010 Nov 1;16(21):5277-87. doi: 10.1158/1078-0432.CCR-10-0791. Epub 2010 Oct 26.
本文引用的文献
1
An inventory of shedding data from clinical gene therapy trials.
J Gene Med. 2007 Oct;9(10):910-21. doi: 10.1002/jgm.1096.
2
A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors.
Cancer Biol Ther. 2007 May;6(5):648-53. doi: 10.4161/cbt.6.5.4004. Epub 2007 Feb 13.
3
Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Cancer Sci. 2006 Jun;97(6):554-61. doi: 10.1111/j.1349-7006.2006.00206.x.
4
Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
J Clin Oncol. 2006 Apr 10;24(11):1689-99. doi: 10.1200/JCO.2005.03.4116. Epub 2006 Feb 27.
5
Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery.
Br J Cancer. 2005 Apr 25;92(8):1414-20. doi: 10.1038/sj.bjc.6602494.
6
Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development.
Gene Ther. 2004 Oct;11 Suppl 1:S98-S108. doi: 10.1038/sj.gt.3302378.
7
Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points.
Hum Gene Ther. 2003 Mar 20;14(5):425-33. doi: 10.1089/104303403321467199.
8
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.
Gene Ther. 2003 Mar;10(5):386-95. doi: 10.1038/sj.gt.3301928.
9
10
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
J Clin Oncol. 2001 Jan 15;19(2):289-98. doi: 10.1200/JCO.2001.19.2.289.
Zotero 插件